China Cognition and Aging Study
关键词
抽象
描述
This study involved participants including amnestic mild cognitive impairment (aMCI), sporadic Alzheimer's disease (SAD), familial Alzheimer's disease (FAD), Vascular cognitive impairment (VCI), and APOE gene cohort (cognitive normal subjects). Research contents are as follow:
1. Neuropsychological characteristics of Chinese aMCI, SAD, VCI: analyze the cognitive function, daily living ability and mental behavior symptoms using MMSE, MoCA, etc. during the baseline and follow-up period.
2. Neuroimaging of Chinese aMCI, SAD, and VCI: explore the neuroimaging characteristics and disease evolution characteristics through the apocalyptic atrophy, cortical thickness of structure MRI, and standardized uptake values of functional imaging FDG-PET.
3. Prevention of Chinese aMCI, SAD, and VCI: find the risk factors and environmental factors which were possible related to development of these disease, and propose a preventional strategy for dementia in China.
4. Pathogenesis of Chinese aMCI, SAD, and VCI: test the investigator's findings (risk factors, genetic factors, environmental factors) in this cohort on animal models.
日期
最后验证: | 07/31/2019 |
首次提交: | 08/22/2018 |
提交的预估入学人数: | 08/28/2018 |
首次发布: | 08/30/2018 |
上次提交的更新: | 10/27/2019 |
最近更新发布: | 10/29/2019 |
实际学习开始日期: | 01/09/2008 |
预计主要完成日期: | 12/31/2027 |
预计完成日期: | 12/31/2027 |
状况或疾病
相
手臂组
臂 | 干预/治疗 |
---|---|
Amnestic mild cognitive impairment (MCI) Mild cognitive impairment subjects with memory loss as predominant symptom | |
Sporadic Alzheimer's disease (SAD) Mild to moderate sporadic Alzheimer's disease subjects | |
Familial Alzheimer's disease (FAD) Familial Alzheimer disease subjects with known or unknown mutations | |
Vascular cognitive impairment (VCI) Cognitive impairment subjects caused by cerebral small vessel disease, including vascular cognitive impairment no dementia, vascular dementia, mixes dementia | |
APOE gene cohort Cognitive normal subjects with ApoE ε4 positive or negative |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | All |
取样方式 | Non-Probability Sample |
接受健康志愿者 | 是 |
标准 | Amnestic mild cognitive impairment (aMCI) Inclusion Criteria: 1. Diagnosis according to 2004 Peterson's aMCI criteria. 2. Clinical Dementia Rating (CDR) = 0.5. 3. Memory loss is prominent, and may also be with other cognitive domain impairment. 4. Insidious onset, slow progress. 5. Not reaching the level of dementia. Exclusion Criteria: 1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral vascular disease (Fazekas score ≥ 2 points). 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 3. Other systemic diseases that can cause cognitive impairment(such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 4. Mental and neurodevelopmental retardation. 5. Other diseases known to cause cognitive impairment. 6. Contraindications to nuclear magnetics. 7. Suffering from a disease that cannot be combined with cognitive examination. 8. Refuse to draw blood. 9. Refuse to sign the informed consent at baseline Sporadic Alzheimer's disease (SAD) Inclusion Criteria: 1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. 2. Subjects and their informed persons can complete relevant and follow-up examinations. 3. Subjects or their authorized legal guardians sign the informed consent. Exclusion Criteria: 1. With a family history of dementia. 2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 3. Other systemic diseases that can cause cognitive impairment(such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 4. Mental and neurodevelopmental retardation. 5. Other diseases known to cause cognitive impairment. 6. Contraindications to nuclear magnetics. 7. Suffering from a disease that cannot be combined with cognitive examination. 8. Refuse to draw blood. 9. Refuse to sign the informed consent at baseline Familial Alzheimer's disease (FAD) Inclusion Criteria: 1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. 2. Members who carry mutations or not carry mutations in familial Alzheimer's disease pedigree (familial Alzheimer disease is defined as at least two first- degree relatives). 3. Aged 18 (inclusive) or older. 4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. A diagnosis of mild cognitive impairment (MCI) is assigned according to Petersen criteria. Exclusion Criteria: 1. Under age 18. 2. Medical or psychiatric illness that would interfere in completing initial and follow-up visits. 3. No one who can serve as a study informant. 4. With current or past neurological or psychiatric illnesses such as schizophrenia, epilepsy, brain tumors, severe head trauma and other diseases which can induce dementia. 5. With history of alcohol or drug abuse. Vascular cognitive impairment (VCI) Inclusion Criteria: 1. Diagnosis according to the criteria for small vessel VCI, with the following three core elements: 1. Cognitive impairment: memory decline can be highlighted 2. Vascular factors 3. Causal relationship between cognitive impairment and vascular factors 2. Cognitive impairment lasts for 3 months or more, and the CDR global score ≥0.5 point. 3. All patients need to meet the following MRI criteria: 1. Multiple (≥3) small infarcts (3-20 mm in diameter) with or without any degree of white matter lesions (WML); or moderate to severe WML (Fazekas score ≥ 2) , with or without small infarction; or ≥ 1 small infarct in key parts of the cortex, such as: caudate nucleus, globus pallidus, thalamus and so on. 2. No WML caused by cortical infarction, watershed infarction, hemorrhage, hydrocephalus, or other causes (such as multiple sclerosis). 3. No hippocampus or entorhinal cortex atrophy, Medial Temporal Lobe Atrophy (MTA)≤ 1 point. 4. Subjects and their informed persons can complete relevant and follow-up examinations. 5. Subjects or their authorized legal guardians sign the informed consent. Exclusion Criteria: 1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 2. Other systemic diseases that can cause cognitive impairment(such as liver, renal, and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 3. Other diseases known to cause cognitive impairment. 4. Hereditary or inflammatory small vessel disease, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 5. Contraindications to nuclear magnetics. 6. Refuse to draw blood. 7. Refuse to sign the informed consent at baseline. APOE gene cohort Inclusion Criteria: 1. Aged 18 (inclusive) or older. 2. APOE genotyping has to be obtained from all subjects. 3. Normal MMSE and MoCA evaluations. MMSE>19 points for illiteracy, >24 points for those educated less than 7 years, >27 points for those educated equal to or more than 7 years. MoCA>13 points for illiteracy, >19 points for those educated less than 7 years, >24 points for those educated equal to or more than 7 years. Exclusion Criteria: 1. Subjects with abnormal MMSE or MoCA scores. 2. Subjects with a history of cerebral infarction, traumatic brain injury confirmed by MRI imaging. 3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.). 4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.). 5. Mental and neurodevelopmental retardation. 6. Other diseases known to cause cognitive impairment. 7. Contraindications to nuclear magnetics. 8. Refuse to draw blood. 9. Refuse to sign the informed consent at baseline. |
结果
主要结果指标
1. The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design [an average of 2 years]
2. The conversion rate of normal to MCI to AD in Chinese [an average of 2 years]
3. The biomarkers for normal (pre-MCI), MCI and AD diagnosis [an average of 2 years]
4. The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels [an average of 2 years]